

SUPPLEMENTAL TABLES

TABLE S1: Patient Disposition and Time Period on SO Before Discontinuation

SO follow-up time (months)	Patients continuing SO therapy	Patients who ended SO follow-up	Reason for end of SO follow-up			
			<i>FKC discharge / switch to HD treatment</i>	<i>Prescription of new PB added on to SO therapy</i>	<i>Prescription of new PB to replace SO</i>	<i>No further PB prescriptions recorded</i>
4	205	53	5	5	5	38
5	166	39	1	3	8	27
6	107	59	5	0	4	50
End of 6 months (total N)	107	151	11	8	17	115

Values are expressed as number of patients

Abbreviations: FKC – Fresenius Kidney Care; PB – phosphate binder; SO – sucroferric oxyhydroxide

TABLE S2: Phosphate Binder Use among Patients with In-Range Serum Phosphorus Levels at Baseline

Baseline month	Patients with sP recorded	n/N (%) sP ≤ 5.5 mg/dL	Baseline binder for sP ≤ 5.5 patients (FreseniusRx & FKC EHR database)				
			Calcium acetate	Sevelamer	Lanthanum carbonate	> 1 PB recorded*	No PB recorded
-3	226	68/226 (30.1%)	16/68 (23.5%)	22/68 (32.3%)	0	7/68 (10.3%)	23/68 (33.8%)
-2	232	59/232 (25.4%)	16/59 (27.1%)	20/59 (33.9%)	0	6/59 (10.2%)	17/59 (45.8%)
-1	248	64/248 (25.8%)	17/64 (26.6%)	20/64 (31.3%)	2/64 (3.1%)	6/64 (9.4%)	19/64 (29.7%)

Baseline month is calculated relative to SO treatment initiation

Values are expressed as n/N (%) of patients

Abbreviations: FKC EHR – Fresenius Kidney Care electronic health records; PB – phosphate binder; sP – serum phosphorus

* >1 PB refers to a combination of sevelamer, calcium acetate, and/or lanthanum carbonate

TABLE S4: Oral Calcimimetics and Active Vitamin D Use among Patients with In-Range Serum Phosphorus for ≥ 1 Quarter of SO Follow-up

Parameter	Baseline	SO follow-up	P-value
Patients with serum phosphorus ≤ 5.5 mg/dL for ≥ 3 months of SO follow-up ($n=110$)			
Patients treated with oral cinacalcet, n(%)	33 (30%)	39 (35.50%)	0.058
Oral cinacalcet dose (mg/day)	48.6 (4.8)	46 (4.4)	0.4
Patients treated with oral active vitamin D, n(%)*	64 (58.20%)	68 (61.80%)	0.16
Oral calcitriol dose (mcg/day)	0.46 (0.04)	0.45 (0.04)	0.6
Subset of patients with serum phosphorus > 5.5 mg/dL at baseline ($n=63$)			
Patients treated with oral cinacalcet, n(%)	21 (33.3%)	23 (36.5%)	0.4
Oral cinacalcet dose (mg/day)	54 (5.3)	41.6 (4.7)	0.015
Patients treated with oral active vitamin D, n(%)*	37 (58.70%)	31 (61.90%)	0.16
Oral calcitriol dose (mcg/day)	0.48 (0.07)	0.51 (0.07)	0.3

Values are expressed as least-squared mean (standard error), or n(%) of patients. p-values compare summary estimates between treatment periods.

Abbreviations: SO – sucroferric oxyhydroxide

* Oral active vitamin D includes calcitriol, doxercalciferol, and alfacalidol